Cenglang Shengwu develops IVD diagnostic instruments, reagents, and biomedical research instruments with a specific focus on the flow cytometry field. The company is working to automate and routinize flow cytometry technology and to make analytical workflows simpler and more intelligent. Its product strategy emphasizes automation, normalization of procedures, and user-friendly intelligent analysis. Recently Cenglang Shengwu completed a near-RMB100 million Series B financing to support its growth. The company intends to use the financing to accelerate progress toward higher-end and routinized flow cytometry applications and to achieve more substantial results. No operating metrics were disclosed in the article.

Total raised

$14M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2024